Development and application of adenoviral vectors for gene therapy of cancer

Cancer Gene Therapy

Volumn 6, Issue 2, 1999, Pages 113-138

  Zhang, Wei Wei ^a  

^a GenStar Therapeutics Corporation   (United States)

Author keywords

Adenoviral vector; Cancer gene therapy

Indexed keywords

CANCER VACCINE;

ADENOVIRUS; BIOLOGICAL MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

ADENOVIRIDAE; CANCER VACCINES; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 0033088695     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700024     Document Type: Article

References (240)

1. Horwitz MS. Adenoviridae and their replication. In: Field BN, Knipe DM, Chanock RM, et al, eds. Fundamental Virology. 2nd Ed. New York: Raven Press; 1990: 771-813.
2. Sussenbach JS. The structure of the genome. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:35-124.
3. Philipson L. Adenovirus assembly. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:309-337.
4. Stratford-Perricaudet L, Perricaudet M. Gene transfer into animals: the promise of adenovirus. In: CohenHaguenauer O, Boiron M, eds. Human Gene Transfer. Colloque INSERM/John Libbey Eurotext Ltd.; 1991:51-61.
5. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Clifton, NJ: The Humana Press; 1991:109-128.
6. Nevins JR. Transcriptional activation by the adenovirus E1A proteins. Semin Virol. 1993;4:25-31.
7. Pettersson U, Roberts RJ. Adenovirus gene expression and replication: a historical review. In: Botchan M, Glodzicker T, Sharp PA, eds. Cancer Cells Volume 4: DNA Tumor Viruses. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory; 1986:37-57.
8. Wold WSM, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology. 1991;184:1-8.
9. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol. 1985;56:250-257.
10. Shaw AR, Ziff EB. Transcriptions from the adenovirus-2 major late promoter yield a single early family of 3′ coterminal mRNA and five late families. Cell. 1980;22: 905-916.
11. Straus SE. Adenovirus infections in humans. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:451-496.
12. 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol. 1995;69:2257-2263.
13. Philipson L, Londerg-Holm K, Pettersson U. Virus-receptor interaction in an adenovirus system. J Virol. 1968;2:1064-1075.
14. Defer C, Belin MT, Caillet-Boudin ML, Boulanger P. Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J Virol. 1990;64:3661-3673.
15. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
16. Dales S, Chardonnet Y. Early events in the interaction of adenoviruses with HeLa cells: association with microtubules and the nuclear pore complex during vectorial movement of the inoculum. Virology. 1973;56:465-483.
17. 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319.
18. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp RGD: sequence in adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol. 1993;67: 5198-5205.
19. Fitzgerald DJP, Trowbridge IS, Pastan I, et al. Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc Natl Acad Sci USA. 1983;80:4134-4138.
20. Fitzgerald DJP, Padmanabhan R, Pastan I, et al. Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell. 1983;32:607-617.
21. Yoshimura K, Rosenfeld MA, Seth P, Crystal RG. Adenovirus-mediated augmentation of cell transfection with unmodified plasmid vectors. J Biol Chem. 1993;268:2300-2303.
22. Seth PJ. Adenovirus-dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein. J. Virol. 1994;68:1204-1206.
23. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol. 1988;62:2321-2328.
24. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell. 1993;75:477-486.
25. Green M, Daesch GE. Biochemical studies on adenovirus multiplication: kinetics of nucleic acid and protein synthesis in suspension cultures. Virology. 1961;13:169-176.
26. Kelly TJ, Jr. Adenovirus DNA replication. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:271-308.
27. Lechner RL, Kelly TJ, Jr. The structure of replicating adenovirus 2 DNA molecules. Cell. 1977;12:1007-1020.
28. Rekosh DMK, Russell WC, Bellett AJD. Identification of a protein linked to the ends of adenovirus DNA. Cell. 1977;11:283-295.
29. Guggenheimer RA, Nagata K, Field J, et al. In vitro synthesis of full-length adenoviral DNA. In: Cozzarelli N, ed. UCLA Symposia on Mechanisms of DMA Replication and Recombination. New York: Alan R. Liss; 1983:395-421.
30. Pruijn GJ, Van Driel W, Van der Vliet PC. Nuclear factor III, a novel sequence-specific DNA-binding protein from HeLa cells stimulating adenovirus DNA replication. Nature. 1986;322:656-659.
31. Hammarskjoeld M-L, Winberg G. Encapsidation of adenovirus 16 DNA is directed by a small DNA sequence at the left end of the genome. Cell. 1980;20:787-795.
32. Robbinson CC, Tibbetts C. Polar encapsidation of adenovirus DNA: evolutionary variants reveal dispensable sequences near the left ends of Ad3 genomes. Virology. 1984;137:276-286.
33. Hearing P, Samulsi RJ, Wishart WL, Shenk T. Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 genome. J Virol. 1987;671:2555-2558.
34. Grable M, Hearing P. Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J Virol. 1990;64:2047-2056.
35. Grable M, Hearing P. Cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J Virol. 1992;6:723-731.
36. Schmid SI, Hearing P. Bipartite structure and functional independence of adenovirus type 5 packaging elements. J Virol. 1997;71:3375-3384.
37. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-72.
38. Stow ND. Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. J Virol. 1981;37:171-180.
39. Chinnadurai G, Chinnadurai S, Brussa J. Physical mapping of a large-plaque mutation of adenovirus type 2. J Virol. 1979;32:623-628.
40. Berkner KL, Sharp PA. Generation of adenovirus by transfection of plasmids. Nucleic Acids Res. 1983;17: 6003-6021.
41. Graham FL. Covalently closed circles of human adenovirus DNA. EMBO J. 1984;3:2917-2922.
42. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988;163: 614-617.
43. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
44. Ketner G, Spencer F, Tugendreich S, Connelly C, Hieter P. Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci USA. 1994;91:6186-6190.
45. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805-4810.
46. Crouzet J, Naudin L, Orsini C, et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA. 1997;94:1414-1419.
47. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through cre-lox recombination. J Virol. 1997;71:1842-1849.
48. Miyake S, Makimuru M, Kanagae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus gene. Proc Natl Acad Sci USA. 1996;93: 1320-1324.
49. Fu S, Deisseroth AB. Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum Gene Ther. 1997;8:1321-1330.
50. Green M, Wold WSM. Human adenoviruses: growth, purification, and transfection assay. Methods Enzymol. 1979;58:425-435.
51. Graham FL. Growth of 293 cells in suspension culture. J Gen Virol. 1987;68:937-940.
52. Green M, Pina M. Biochemical studies on adenovirus multiplication: properties of highly purified tumorigenic human adenoviruses and their DNAs. Proc Natl Acad Sci USA. 1964;51:1251-1259.
53. Huyghe BG, Liu X, Sutjipto S, et al. Purification of type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther. 1995;6:1403-1416.
54. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992;68:143-155.
55. Pinteric L, Taylor J. The lowered drop method for the preparation of specimens of partially purified virus lysates for quantitative electron micrographic analysis. Virology. 1962;18:359-371.
56. Lawrence WC, Ginsberg H. Intracellular uncoating of type 5 adenovirus deoxyribonucleic acid. J Virol. 1967;1: 851-867.
57. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498-7509.
58. Zhang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
59. Zhang W-W, Alemany R, Wang J, et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther. 1995;6:155-164.
60. Zhang W-W, Koch P, Roth JA. Detection of wild-type contamination in recombinant adenoviral preparation by PCR. BioTechniques. 1995;18:444-447.
61. Zhang W-W. Adenovirus as a system for delivering and expressing tumor-suppressor genes in tumor cells. Methods. 1995;8:198-214.
62. Shabram PW, Giroux DD, Goudreau AM, et al. Analytical anion-exchange HPLC of recombinant type 5 adenoviral particles. Hum Gene Ther. 1997;8:453-465.
63. Boucher RC, Knowles MR. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. Hum Gene Ther. 1994;5:615-639.
64. Lochmuller H, Jani A, Huard J, et al. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (δE1+E3) during multiple passages in 293 cells. Hum Gene Ther. 1994;5:1485-1491.
65. Smith CD, Craft DW, Shiromot RS, et al. Alternative cell line for virus isolation. J Clin Microbiol. 1986;24:265-268.
66. Jones N, Shenk T. Isolation of deletion and substitution mutants of adenovirus type 5. Cell. 1978;13:181-188.
67. Ghosh-Choudhury G, Haj-Ahmad Y, Graham FL. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full-length genomes. EMBO J. 1987;6:1733-1739.
68. Aiello L, Guilfoyle R, Huebner K, Weinmann R. Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells HEK-Ad-5 or 293. Virology. 1979;94:460-469.
69. Shenk T, Jones N, Colby W, et al. Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp Quant Biol. 1979;44:367-375.
70. Dai Y, Schwarz EM, Gu D, Shang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA. 1995;92:1401-1405.
71. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.
72. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell BC. Adenovirus-mediated gene transfer to cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1994;1:192-200.
73. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015.
74. Dong JY, Wang D, Van Ginkel FW, Pascual DW, Frizzell RA. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther. 1996;7:319-331.
75. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997;8:37-44.
76. Imperiale MJ, Kao H-T, Feldman JR, et al. Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity. Mol Cell Biol. 1984;4:867-874.
77. Spergel JM, Hsu W, Akira S, et al. NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J Virol. 1992;66:1021-1030.
78. Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell. 1979;17:683-689.
79. Grubb BR, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature. 1994;371:802-806.
80. Yang Y, Nunes FA, Berencsi K, et al. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy for cystic fibrosis. Nat Genet. 1994;7:362-369.
81. Yang Y, Joos KU, Su Q, Ertl HCJ, Wilson JM. Immune responses to viral antigens versus transgene products in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996;3:137-144.
82. Song W, Kong H-L, Traktman P, Crystal RG. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum Gene Ther. 1997;8:1207-1217.
83. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. Hum Gene Ther. 1994;5:1217-1229.
84. Wadsworth SC, Zhou H, Smith AE, Kaplan JM. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J Virol. 1997;71:5189-5196.
85. Kaplan JM, St George JA, Pennington SE, et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 1996;3:117-127.
86. Mastrangeli A, Harvey BG, Yao J, et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther. 1996;7:79-87.
87. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994;8:42-51.
88. Mullbacker A, Bellett AJ, Hla RT. The murine cellular immune response to adenovirus type 5. Immunol Cell Biol. 1989;67:31-39.
89. Zinkernagel RM. Immunity of viruses. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press; 1993: 1211-1250.
90. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.
91. Descamps V, Duffour MT, Mathieu MC, et al. Strategies for cancer gene therapy using adenoviral vectors. J Mol Med. 1996;74:183-189.
92. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
93. Zhang W-W, Fang X. Gene therapy strategies for cancer. Exp Opin Invest Drugs. 1995;4:487-514.
94. Montenarh M. Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. Crit Rev Oncog. 1992;3:233-256.
95. Tominaga O, Hamelin R, Remvikos Y, et al. p53 from basic research to clinical applications. Crit Rev Oncog. 1992;3:257-282.
96. Bartek J, Bartkova J, Vojtessek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991; 6:1699-1703.
97. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
98. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912-915.
99. Cai DW, Mukhopadhyay T, Liu Y, et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther. 1993;4:617-624.
100. Zhang W-W, Fang X, Branch CD, et al. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. BioTechniques. 1993;15:868-872.
101. Wang J, Bucana CD, Roth JA, et al. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for tumoricidal effect of Ad5CMV-p53. Cancer Gene Ther. 1995;2:9-17.
102. Liu T-J, Zhang W-W, Taylor DL, et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994;54:3662-3667.
103. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 1994;5:1079-1088.
104. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
105. INK4 gene mediated by an adenovirus vector. Cancer Res. 1995;55:3250-3253.
106. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997;3:313-319.
107. Ledwith BJ, Manam S, Kraynak AR, et al. Antisense-fos RNA causes partial reversion of the transformation phenotypes induced by the c-Ha-ras oncogene. Mol Cell Biol. 1990;10:1545-1555.
108. Sklar MD, Thompson E, Welsh MJ, et al. Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol. 1991;11:3699-3710.
109. Mukhopadhyay T, Tainsky M, Cavender AC, et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991;51: 1744-1748.
110. Alemany R, Ruan S, Katoaka M, et al. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. 1996;3:296-301.
111. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-8043.
112. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
113. Borrelli E, Heyman R, Hsi M, et al. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA. 1988;85:7572-7576.
114. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991;3:608-614.
115. Mullen CA, Kilstrup ME, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89:33-37.
116. Huber BE, Austin EA, Good SS, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 1993;53:4619-4626.
117. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1: 279-287.
118. Garver RI, Goldsmith KT, Rodu B, et al. Strategy for achieving selective killing of carcinomas. Gene Ther. 1994;1:46-50.
119. Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
120. Colak A, Goodman JC, Chen S-H, Woo S, Grossman R, Shine HD. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Hum Gene Ther. 1995;6:1317-1322.
121. Andersen L, Kilstrup M, Neuhard J. Pyrimidine, purine, and nitrogen control of cytosine deaminase synthesis in Escherichia coli K12: involvement of the glnG and purR genes in the regulation of codA expression. Arch Microbiol. 1989;152:115-118.
122. Austin EA, Huber BE. A first step in development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 43:380-387.
123. Hirschowitz EA, Ohwada A, Pascal WR, et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 1995;6:1055-1063.
124. Hart I. Tissue-specific promoters in targeting systemically delivered gene therapy. Semin Oncol. 1996;23:154-158.
125. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994;54:5258-5261.
126. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther. 1995;6:881-893.
127. Smith MJ, Rousculp MD, Goldsmith KT, et al. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther. 1994;5:29-35.
128. Manome Y, Abe M, Hagen MR, et al. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 1994;54:5408-5413.
129. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest. 1995;96:2775-2782.
130. Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res. 1995; 55:3105-3109.
131. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55: 5283-5287.
132. Kanai F, Shiratori Y, Yoshida Y. Gene therapy for α-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology. 1996;23:1359-1368.
133. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993;53:963-967.
134. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56:5638-5646.
135. Depacz NG. Sulla acoparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia. 1912;9:82-88.
136. Rowe WP, Huebner R, Gilmore LK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exper Biol Med. 1953;84:570-573.
137. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA. 1992;89: 7742-7746.
138. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 1993;7:546-554.
139. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993;53:891-898.
140. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995;10:2263-2270.
141. Chang JY, Xia W, Shao R, et al. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene. 1996;13:1405-1412.
142. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987;156:107-121.
143. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
144. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-645.
145. Hallenbeck PL, Chang YN, Hay C, et al. Novel tumor-specific replication-competent adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1996;3:19-20.
146. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
147. Hilleman MR. Epidemiology of adenovirus respiratory infections in military recruit populations. Ann N Y Acad Sci. 1957;67:262.
148. Van Der Veen J, Kok G. Isolation and typing of adenoviruses recovered from military recruits with acute respiratory disease in the Netherlands. Am J Hyg. 1957;65:119.
149. Van Der Veen J, Oei JG, Abarbanel MFW. Patterns of infections with adenovirus types 4, 7, and 21 in military recruits during a 9-year survey. J Hyg Camb. 1969;67:255.
150. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol. 1992; 158:39-66.
151. Bueschner EL. Respiratory disease and the adenoviruses. Med Clin North Am. 1967;51:769-779.
152. Chanock RM, Ludwig W, Huebner RJ, Gate TR, Chu LW. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. JAMA. 1966;196:445-452.
153. Top FH. Control of adenovirus acute respiratory disease in U.S. army trainees. Yale J Biol Med. 1975;48: 185-195.
154. Graham FC. Transformation by and oncogenicity of human adenoviruses. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:339-398.
155. Rubin BA, Rorke LB. Adenovirus vaccine. In: Plotkin SA, Mortimer EA, Jr., eds. Vaccine. Philadelphia: WB Saunders; 1988:492-512.
156. Fox JP, Brandt CD, Wasserman FE, Hall CE. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VI. Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. Am J Epidemiol. 1969; 89:25-50.
157. Hung PP, Morin JE, Lubeck MD, et al. Recombinant adenovirus as a vehicle for the HBV surface antigen or HIV envelope protein genes. In: Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy. New York: Alan R. Liss; 1988:349-3618.
158. Alkhatib G, Briedis DJ. High-level eucaryotic in vivo expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system. J Virol. 1988;62:2718-2727.
159. Johnson DC, Ghosh-Choudhury G, Smiley JR, Fallis LY, Graham FL. Abundant expression of herpes simplex virus glycoprotein gB using and adenovirus vector. Virology. 1988;164:1-14.
160. Grunhaus A, Horwitz MS. Adenoviruses as cloning vectors. Semin Virol. 1992;3:237-252.
161. Pardoll D. Cancer vaccines. Trends Pharmacol Sci. 1993; 14:202-208.
162. Fearon ER, et al. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
163. Henney CS, Kuribayaski K, Kern DE, et al. Interleukin 2 augments natural killer cell activity. Nature. 1981;291: 335-338.
164. Lotze MT, Grimm EA, Mazumder A, et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41: 4420-4425.
165. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318-1321.
166. Parkinson DR. Interleukin 2 in cancer therapy. Semin Oncol. 1988;15:10-26.
167. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
168. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther. 1993;4:703-711.
169. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 1996;3:11-17.
170. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SLC. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther. 1996;3: 980-987.
171. Bramson JL, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7:333-342.
172. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996; 7:1995-2002.
173. Dessureault S, Graham F, Gallinger S. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector. Ann Surg Oncol. 1996; 3:317-324.
174. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008-4027.
175. Freeman GJ, Freeman AS, Segil JM, et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1987;143: 2714-2722.
176. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
177. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
178. Boon T, Coulie P, Marchand M, Wycnants P, Wolfel T, Brichard V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In: DeVita VT, Hellman S, Rosenberg S, eds. Important Advances in Oncology. Philadelphia: J.B. Lippincott; 1994:53.
179. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1:-4.
180. Pardoll DM. Tumor antigens: a new look for the 1990s. Nature. 1994;369:357-358.
181. Zhai Y, Yang JC, Kawakami Y, et al. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996; 156:700-710.
182. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today. 1995;16:117-121.
183. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol. 1996;156:225-231.
184. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen
185. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996;7:215-222.
186. Imler J-L, Chartier C, Dreyer D, et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther. 1996;3:75-84.
187. Tacket CO, Losonsky G, Lubeck MD, et al. Initial safety and immunogenicity studies of an oral adenohepatitis B vaccine. Vaccine. 1992;10:673-676.
188. Klessig DF, Brough DE, Cleghon V. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol. 1984;4:1354-1362.
189. Rice SA, Klessig DF. Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J Virol. 1985;56:767-778.
190. Brough DE, Cleghon V, Klessig DF. Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology. 1992;190:624-634.
191. Weinberg DH, Ketner G. A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc Natl Acad Sci USA. 1983;80:5383-5386.
192. Bridge E, Ketner G. Redundant control of adenovirus late gene expression by early region 4. J Virol. 1989;63: 631-638.
193. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2A from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol. 1996; 70:4173-4178.
194. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2A deleted. J Virol. 1996;70:7030-7038.
195. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2A wild-type and E2A-deleted vectors. Hum Gene Ther. 8:1275-1286.
196. Schaack J, Guo X, Ho WY, Karlok M, Chen C, Ornelles D. Adenovirus type 5 precursor terminal protein-expressing 293 and HeLa cell lines. J Virol. 1995;69:4079-4085.
197. Amalfitano A, Begy CR, Chamberlain JS. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA. 1996;93:3352-3356.
198. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther. 1997;4:258-263.
199. Krouglik V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX-defective adenovirus type 5 mutants. Hum Gene Ther. 1995;6:1575-1586.
200. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-8943.
201. Lieber A, He CY, Kirillova I, Kay M. Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared wilh first-generation vectors in vitro and in vivo. J Virol. 1996;70:8944-8960.
202. Deuschle U, Meyer WK-H, Thiesen H-J. Tetracycline-reversible silencing of eukaryotic promoters. Intervirology. 1993;36:79-83.
203. Robinson AJ, Younghusband BH, Bellett AJD. A circular DNA protein complex from adenoviruses. Virology. 1973;56:54-69.
204. Challburg MD, Ostrove J, Kelly TJ, Jr. Initiation of adenovirus DNA replication: detection of covalent complexes between nucleotide and the 80-kDa terminal protein. J Virol. 1982;41:265-270.
205. Casjens S. Nucleic acid packaging by viruses. In: Casjens S, ed. Virus Structure and Assembly. Boston: Jones and Bartlett; 1985:75-147.
206. Feiss M, Fisher RA, Siegele DA, et al. Packaging of the bacteriophage λ chromosome: a role for the base sequences outside cos. Virology. 1979;92:56-67.
207. Levrero M, Barban V, Manteca S, et al. Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene. 1991;101:195-202.
208. Young CSH, Shenk T, Ginsberg HS. The genetic system. In: Ginsberg HS, ed. The Adenoviruses. New York: Plenum Press; 1984:125-172.
209. Gluzman Y, Van Doren K. Palindromic adenovirus type 5-simian virus 40 hybrid. J Virol. 1983;45:91-103.
210. Deuring R, Klotz G, Doerfler W. An unusual symmetric recombinant between adenovirus type 12 DNA and human cell DNA. Proc Natl Acad Sci USA. 1981;78:3142-3146.
211. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. Sindbis virus expression vectors: packaging of RNA relicons by using defective helper RNAs. J Virol. 1993;67:6439-6446.
212. Mitani K, Graham F, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA. 1995;92:3854-3858.
213. Fisher KJ, Choi H, Burda J, et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996;217:11-22.
214. Kumary-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14-kb dystrophin cDNA to muscle cells. Hum Mol Gen. 1996;5:913-921.
215. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA. 1996;93:5731-5736.
216. Alemany R, Dai Y, Lou YC, et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods. 1997;68:147-159.
217. Alemany R, Dai Y, Lou Y-C, Prokopenko E, Zhang W-W. Complementation of adenoviral vectors with a helper virus partially deleted in the packaging signal. In: Abstracts of Papers Presented at the 1996 Meeting on Gene Therapy. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory; 1996:18.
218. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA. 1996;93:13565-13570.
219. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol. 1997;71:3293-3298.
220. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 1996;3:965-972.
221. Chen HH, Mack LM, Kelly R, Ontell M, Sochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA. 1997;94:1645-1650.
222. Vincent N, Rabot T, Gildenkrantz H, et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet. 1993;5:130-134.
223. Acsadi G, Lochmuller H, Jani A, et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther. 1996;7: 129-140.
224. Michael S, Hong J, Curiel D, Engler J. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 1995;2:660-669.
225. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 1996;70: 6831-6838.
226. Krasnyky VN, Mikheeva GV, Douglas JT, Curiel D. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 1996;70: 6839-6846.
227. Douglas J, Rogers B, Rosenfeld M, Michael S, Feng M, Curiel D. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 1996;14:1574-1577.
228. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparin-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 1996;14:1570-1573.
229. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 1997;71;10:7663-7669.
230. Fender P, Ruigrok RWH, Gout E, Buffet S, Chroboczek J. Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol. 1997;15:52-56.
231. Stewart PL, Burnett RM, Cyrklaff M, et al. Image reconstruction reveals the complex molecular organization of adenovirus. Cell. 1991;67:145-154.
232. Wohlgemuth JG, Kang SH, Bulboaca GH, Nawotka KA, Calos MP. Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Ther. 1996;3:503-512.
233. Balague C, Kalla M, Zhang W-W. Adeno-associated Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol. 1997;71:3299-3306.
234. Rabson AS, O'Connor CT, Berezesky IK, Paul FJ. Enhancement of adenovirus growth in African green monkey kidney cell cultures by SV40. Proc Soc Exp Biol Med. 1964;116:187-190.
235. Heubner RJ, Chanock RM, Rubin BA, Casey MJ. Induction by adenovirus type 7 of tumors in hamsters having the antigenic characteristics of SV40 virus. Proc Natl Acad Sci USA. 1964;52:1333-1340.
236. Lewis AM, Jr, Baum SG, Prigge KO, Rowe WP. Occurrence of adenovirus SV40 hybrids among monkey kidney cell-adapted strains of adenovirus. Proc Soc Exp Biol Med. 1966;122:214-218.
237. Rapp F, Melnick JL, Butel JS, Kitahara T. The incorporation of SV40 genetic material into adenovirus 7 as measured by intranuclear synthesis of SV40 tumor antigen. Proc Natl Acad Sci USA. 1964;52:1348-1352.
238. Bilbao G, Feng M, Rancourt C, Jackson W, Curiel D. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J. 1997;11:624-634.
239. Feng M, Jackson W, Goldman C, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol. 1997;15:866-870.
240. Goldsmith KT, Curiel DT, Engler JA, Garver RI, Jr. Trans-complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther. 1994;5:1341-1348.